RBC’s Epigenetics Toolbox: Enabling Epigenetic Research and Drug Discovery

We respect your privacy, by clicking ‘Watch On Demand’ you agree to receive our e-newsletter, including information on Podcasts, Webinars, event discounts and online learning opportunities. For further information on how we process and monitor your personal data click here. You can unsubscribe at anytime.

This FREE webinar was recorded on:
November 20, 2014
11:00 AM - 12:00 PM EST

Epigenetic enzymes control the mechanics of genetic expression, acting as "on" and "off" switches for the human genome.

Malfunctions of these enzymes are implicated in a number of cancer, immunological, and neurodegenerative conditions and are the subject of intense research in the pharmaceutical industry to validate them as targets for a new generation of cancer drugs.

Research involving these epigenetic targets is a new frontier, especially for methyltransferase and bromodomain proteins. For this reason, scientists are faced with a variety of problems in protein production, assay development, assay detection, assay kit selection, and the technologies and processes for hit confirmation.

This webinar will explore and provide answers and solutions to these common problems in epigenetic research.

By attending this webinar you will:

1  Learn about the products and tools used for epigenetic research
2: Explore the biochemical based assays that provide epigenetic hit/lead identification
3:  Identify the common problems and mistakes in epigenetic biochemical assays
 

Have Your Say
Rate this feature and give us your feedback in the comments section below

Presenters:

Dr. Ekaterina Kuznetsova
Director of Product Development
Reaction Biology Corp.
We respect your privacy, by clicking ‘Watch On Demand’ you agree to receive our e-newsletter, including information on Podcasts, Webinars, event discounts and online learning opportunities. For further information on how we process and monitor your personal data click here. You can unsubscribe at anytime.
Sponsored By:
Reaction Biology Corp.